ClinicalTrials.gg
CompletedNCT03010228Updated Apr 5, 2023

Study Assessing the Safety, Immunogenicity and Dose Response of VLA15, A New Vaccine Candidate Against Lyme Borreliosis

A Phase 1 interventional study of VLA15 with Alum and VLA15 without Alum in Lyme Borreliosis, Nervous System, sponsored by Pfizer. Completed at 5 sites in 2 countries. Open to participants aged 18 Years to 39 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-04-05.

Sponsored by Pfizer · Phase 1, Interventional, and Prevention

From the registry’s dates

  • Primary completion was Sep 2017, 9 years 1 month ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
179
Allocation
Randomized
Ages
18 Years to 39 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 54 studies in Lyme Disease with a site in United States — 15 open to participants now, 17 under way, 2 of them phase 3. Lyme Disease · United States.

Enrollment
13th of 33
179 · median 72
Started
2017
with 2 others
Phase 1
3 of 54
none open now
Registered
18th of 54
by date
Lead sponsor
8 of 54
Pfizer

Among the 54 studies in Lyme Disease with a site in United States, this one is the 13th largest by enrollment of the 33 interventional ones that give a count, is one of 3 that started in 2017, is one of 3 in phase 1, and was the 18th registered.

Lyme Disease

98 studies on the registry are indexed under Lyme Disease; 27 are open to participants now.

Browse Lyme Disease studies →

Open to participants now

15 of the 54 studies in Lyme Disease with a site in United States are open now. Recruiting first, the newest first:

10 more — sign in →

All 15 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 18 Lyme Disease studies recruiting now, 11 (61%) set no upper age limit and 3 (17%) stop at 75 or younger; 7 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 39 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies in Lyme Disease with a site in United States, or all of them as a file.
02

Study summary

Observer-blind, partially randomized, multi-center dose escalation Phase I study in healthy adults below 40 years of age.

180 subjects will be enrolled in 6 treatment groups (different doses; different formulation: with/without adjuvant); vaccinations will be given I.M.(intramuscular) into the deltoid region on Days 0, 28 and 56. Study participants will be followed up until one year after first vaccination.

Booster Extension:

Subjects in the 48µg and 90µg Treatment groups who received a complete Primary immunization schedule will be included into a Booster Extension 13 months after the first immunization.

Read the detailed description

This is an observer-blind, partially randomized, multi-center dose escalation Phase I study which aims to assess the safety, immunogenicity and dose response of VLA15 in healthy adults aged below 40 years.

Overall 180 subjects will be enrolled in 6 treatment groups: VLA15 12µg with and w/o (without) Alum, VLA15 48µg with and w/o Alum, VLA15 90µg with and w/o Alum.

For the first 24 subjects, the study will be open-label and subjects will not be randomized but included into a staggered dose escalation scheme for safety precaution. Thereafter, the study will be conducted observer-blind in respect to the investigators and site staff involved in clinical evaluation of subjects, subjects will be blinded as well. Remaining 156 subjects will be randomized into the 6 treatment groups. I.M. vaccinations are administered on Days 0, 28 and 56 into deltoid region of the non-dominant arm.

The study will investigate the safety and tolerability as well as immunogenicity of VLA15. The primary objective addresses safety and tolerability of the vaccine up to three months after enrollment, i.e. 84 days after first vaccination. The study includes 1 screening visit and 8 outpatient visits from day 0 through day 365. In addition, safety phone calls will be performed.

Booster Extension:

Subjects in the 48µg and 90µg dose Groups at the Belgian site, who received a complete primary immunization schedule (three vaccinations), will be included into a Booster Extension to investigate the safety and immunogenicity of a booster dose of VLA15 administered 13 months after the first immunization. An extension analysis on safety and immunogenicity will be performed after the last subject has completed the last study visit at Month 19. Additionally a M14 interim analysis on immunogenicity data will be performed, when all subjects completed Month 14.

For inclusion in the Booster Extension of this study only subjects are eligible, who were enrolled in Belgium, completed the primary immunization schedule (three vaccinations) and were randomized into 48µg or 90µg dose groups with or without alum. Subjects included in the staggered dose escalation phase will not be asked to participate in the Booster Extension for operational reasons.

03

Conditions studied

  • Lyme Borreliosis, Nervous System

Browse trials for

Keywords

  • VLA15
  • Lyme Borreliosis
  • Multivalent Recombinant OspA Vaccine
04

Who can participate

Ages eligible
18 Years to 39 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy adults ≥18 to \<40 years of age (for US healthy adults ≥ 19 years to \<40 years) at the time of screening. Health status is assessed by investigator at time of screening based on medical history, physical examination, and laboratory parameters.
  • Written obtained from the subject prior to any study related procedures.
  • ≥18.5 and \<30 at Visit 0 (Screening Visit).
  • Men or women; women require a negative pregnancy test at screening. Women with must agree to use an adequate during the entire study.

Booster Extension:

  • Completed Primary immunization schedule (three vaccinations)
  • Randomization into 48µg or 90µg group with or without Alum
  • Written informed consent for Booster Extension obtained from the subject prior to any study related procedures.
  • Enrolled at study site in Belgium
  • Men or women; women require a negative pregnancy test before booster vaccination. Women of childbearing potential must agree to use an adequate contraception during the entire study.

Exclusion criteria

Exclusion Criteria:

  • Pathological findings in any of the investigations (i.e. medical history, physical examination) as deemed by the investigator or any abnormal laboratory parameter of hematology, clinical chemistry, coagulation, RF (Rheumatoid Factor) or ACPA (Anti-citrullinated protein antibodies) at the Screening Visit.
  • Medical history of severe cardiovascular, respiratory (including asthma), metabolic, neurological, hepatic, rheumatic, hematological, gastrointestinal, renal disorders.
  • Medical history of or current musculoskeletal disorders as deemed clinically relevant by the investigator, arthritis or chronic musculoskeletal pain.
  • Previous vaccination against Lyme borreliosis with any () vaccine.
  • Use of any other investigational or non-registered medicinal product within 30 days prior to VLA15 vaccination at Visit 1 (Day 0) and throughout the entire study period.
  • Chronic illness related to Lyme borreliosis (LB), a history of or active symptomatic LB as suspected or diagnosed by a physician. Subjects with a positive serology test result for Borrelia burgdorferi sensu lato (s.l.) antibodies at screening are excluded.
  • Tick bite within 3 weeks prior to screening, or tick bite during vaccination period (i.e. Day 0 to Day 56).
  • Known active infection with Babesia microti (babesiosis) or Anaplasma phagocytophilum (ehrlichiosis).
  • Active or passive immunization four weeks before first vaccination at Visit 1 and up to Day 84 (i.e. 4 weeks after the last VLA15 immunization). Afterwards, vaccinations should be avoided, except for influenza (seasonal or pandemic) vaccines which may be administered after Day 84 (i.e. 4 weeks after the last VLA15 immunization). Subjects susceptible to require a vaccine during the study period (e.g. due to planned travel) should be excluded at screening.
  • Known congenital, hereditary or acquired immunodeficiency, including infection with (HIV), status post organ transplantation or immuno-suppressive therapy within 30 days prior to Day 0 and up to Day 84. Immuno-suppressive therapy is defined as administration of chronic (longer than 14 days) prednisone or equivalent ≥ 0.05 mg/kg/day. Topical and inhaled are allowed.
  • Planned intake of NSAID (Nonsteroidal anti-inflammatory drug) within three days prior and within seven days after any VLA15 vaccination.
  • History of severe reactions and anaphylaxis.
  • History of allergic bronchial asthma and severe allergic rhinoconjunctivitis.
  • Known hypersensitivity or allergic reactions to one of the components of the vaccine.
  • History of disease, including Type I Diabetes mellitus. Subjects with vitiligo or thyroid disease taking thyroid hormone replacement are not excluded.
  • Any in the past 5 years. If treatment for cancer was successfully completed more than 5 years ago and the malignancy is considered to be cured, the subject may be enrolled.
  • Acute febrile infections within 4 weeks prior to first vaccination and body temperature >37.8 C (oral) prior to each vaccination.
  • Known or suspected alcohol abuse, alcohol dependence, i.e. an average of more than approximately 60 g alcohol (approximately 1 liter of beer or 0.5 liter of wine) per day] or illicit drug use within the last year;
  • Inability or unwillingness to avoid more than the usual intake of alcohol (i.e. not more than 60 g alcohol (approximately 1 liter of beer or 0.5 liter of wine) per day) during the 48 hours after vaccination.
  • Pregnancy (positive pregnancy test), lactation or inadequate in women with
  • Inability or unwillingness to provide or not able to understand and comply with protocol requirements, instructions and protocol-stated restrictions.
  • Donation of blood or blood-derived products (e.g. plasma) within 4 weeks prior to Visit 0 (Screening Visit) and during the entire study.
  • Receipt of blood or blood-derived products in the past 3 months prior to Visit 0 (Screening Visit) or anticipation of such products during the entire study.
  • Mental disorder as deemed clinically relevant by the investigator.
  • History of Guillain-Barré-Syndrome (GBS).
  • Any condition which might interfere with study objectives or that would limit the subject's ability to complete the study in the opinion of the investigator.
  • Persons who are committed to an institution (by virtue of an order issued either by the judicial or the administrative authorities).
  • Persons who are in a dependent relationship with the sponsor, an investigator or other study team members, or the study center. Dependent relationships include close relatives and household members (i.e. children, partner/spouse, siblings, parents) as well as employees of the investigator or study center personnel.

Booster Extension:

  • Individual stopping rule was met during the Initial Study.
  • Subject has a known thrombocytopenia, bleeding disorder, or receipt of anticoagulants in the 3 weeks prior to booster vaccination contraindicating I.M. vaccination as judged by the investigator.
  • Pathological findings in the symptom driven physical examination as deemed clinically relevant by the investigator or any clinically significant abnormal laboratory parameter of hematology, clinical chemistry based on investigator judgement at Visit 8. Subjects with a positive test result for RF and ACPA at Visit 8 are excluded.
  • Use of any other investigational or non-registered medicinal product within 30 days prior to VLA15 booster vaccination at Visit 9 and throughout the entire Booster Extension period.
  • Tick bite within 3 weeks prior to booster vaccination (i.e. Visit 9).
  • Known active infection with Babesia microti (babesiosis) or Anaplasma phagocytophilum (ehrlichiosis).
  • Active or passive immunization four weeks before and within 7 days after booster vaccination at Visit 9.
  • Known congenital, hereditary or acquired immunodeficiency, including infection with human immunodeficiency virus (HIV), status post organ transplantation or immuno-suppressive therapy within 30 days prior to booster vaccination and up to 28 days after. Immuno-suppressive therapy is defined as administration of chronic (longer than 14 days) prednisone or equivalent ≥ 0.05 mg/kg/day. Topical and inhaled steroids are allowed.
  • Developed any of the following conditions since enrolment into Initial Study:

    1. Chronic illness related to Lyme borreliosis (LB), a history of or active symptomatic LB as suspected or diagnosed by a physician.
    2. Severe cardiovascular, respiratory (including asthma), metabolic, neurological, hepatic, rheumatic, hematological, gastrointestinal, renal disorders.
    3. Musculoskeletal disorders as deemed clinically relevant by the investigator, arthritis or chronic musculoskeletal pain.
    4. Severe hypersensitivity reactions and anaphylaxis.
    5. Allergic bronchial asthma and severe allergic rhinoconjunctivitis.
    6. Hypersensitivity or allergic reactions to one of the components of the vaccine.
    7. Autoimmune disease, including Type I Diabetes mellitus. Subjects with vitiligo or thyroid disease taking thyroid hormone replacement are not excluded.
    8. Mental disorder as deemed clinically relevant by the investigator.
    9. Guillain-Barré-Syndrome (GBS)
    10. Malignancy
  • Known or suspected alcohol abuse alcohol dependence, i.e. an average of more than approximately 60 g alcohol (approximately 1 liter of beer or 0.5 liter of wine per day) or illicit drug use within the last year.
  • Inability or unwillingness to avoid more than the usual intake of alcohol (i.e. not more than 60 g alcohol (approximately 1 liter of beer or 0.5 liter of wine) per day) during the 48 hours after vaccination.
  • Pregnancy (positive pregnancy test), lactation or inadequate contraception in women of childbearing potential.
  • Inability or unwillingness to provide informed consent or not able to understand and comply with protocol requirements, instructions and protocol-stated restrictions.
  • Any condition which might interfere with study objectives or that would limit the subject's ability to complete the study in the opinion of the investigator.
  • Persons who are committed to an institution (by virtue of an order issued either by the judicial or the administrative authorities).
  • Persons who are in a dependent relationship with the sponsor, an investigator or other study team members, or the study center. Dependent relationships include close relatives and household members (i.e. children, partner/spouse, siblings, parents) as well as employees of the investigator or study center personnel.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
179 participants (actual)

Study arms

  • Active comparator
    VLA15 12 µg with Alum

    VLA15 12 µg (microgram) with Alum has an injection volume of 100 µl (microliter). The amount of Alum per injection is 0.05 mg (milligram).

    Biological: VLA15 with Alum

  • Active comparator
    VLA15 12 µg w/o Alum

    VLA15 12 µg (microgram) without (w/o) Alum (aluminum hydroxide) has an injection volume of 100 µl (microliter).

    Biological: VLA15 without Alum

  • Active comparator
    VLA15 48 µg with Alum

    VLA15 48 µg (microgram) with Alum (aluminum hydroxide) has an injection volume of 400 µl (microliter). The amount of Alum per injection is 0.2 mg (milligram).

    Biological: VLA15 with Alum

  • Active comparator
    VLA15 48 µg w/o Alum

    VLA15 48 µg (microgram) without (w/o) Alum (aluminum hydroxide) has an injection volume of 400 µl (microliter).

    Biological: VLA15 without Alum

  • Active comparator
    VLA15 90 µg with Alum

    VLA15 90 µg (microgram) with Alum (aluminum hydroxide) has an injection volume of 750 µl (microliter). The amount of Alum per injection is 0.375 mg (milligram).

    Biological: VLA15 with Alum

  • Active comparator
    VLA15 90 µg w/o Alum

    VLA15 90 µg (microgram) without (w/o) Alum (aluminum hydroxide) has an injection volume of 750 µl (microliter).

    Biological: VLA15 without Alum

Interventions

  • BiologicalVLA15 with Alum

    Drug pages: VLA15 · Aluminum sulfate · Aluminium sulfate

    I.M. vaccination with a multivalent outer surface protein A (OspA) based vaccine candidate on days 0, 28 and 56; three different doses

  • I.M. vaccination with a multivalent outer surface protein A (OspA) based vaccine candidate on days 0, 28 and 56; three different doses

06

What researchers measure

Primary outcomes

  1. Rate of SAEs to Day 84

    Time frame: up to Day 84 (Month 3) after first vaccination

  2. Rate of related SAEs to Day 84

    Time frame: up to Day 84 (Month 3) after first vaccination

  3. Rate of any solicited or unsolicited Grade 3 or Grade 4 events up to Day 84

    Time frame: up to Day 84 (Month 3) after first vaccination

  4. Rate of any solicited or related unsolicited Grade 3 or Grade 4 events up to Day 84

    Time frame: up to Day 84 (Month 3) after first vaccination

  5. Rate of solicited local AEs within 7 days after each and after any vaccination up to Day 84

    Time frame: up to Day 84 (Month 3) after first vaccination

  6. Rate of solicited systemic AEs within 7 days after each and after any vaccination up to Day 84

    Time frame: up to Day 84 (Month 3) after first vaccination

  7. Rate of unsolicited AEs to Day 84, including clinically significant laboratory parameter changes

    Time frame: up to Day 84 (Month 3) after first vaccination

  8. Rate of related unsolicited AEs to Day 84, including clinically significant laboratory parameter changes

    Time frame: up to Day 84 (Month 3) after first vaccination

Secondary outcomes

  1. Rate of SAEs during the entire study period

    Time frame: up to Day 365 (Month 12)

  2. Rate of related SAEs during the entire study period

    Time frame: up to Day 365 (Month 12)

  3. Rate of any solicited or unsolicited Grade 3 or Grade 4 AEs during the entire study period

    Time frame: up to Day 365 (Month 12)

  4. Rate of any solicited or related unsolicited Grade 3 or Grade 4 AEs during the entire study period

    Time frame: up to Day 365 (Month 12)

  5. Rate of unsolicited AEs during the entire study period

    Time frame: up to Day 365 (Month 12)

  6. Rate of related unsolicited AEs during the entire study period

    Time frame: up to Day 365 (Month 12)

  7. Changes in laboratory parameters and rate of subjects with abnormal laboratory parameter

    Time frame: up to Day 365 (Month 12)

  8. GMTs (Geometric Mean Titre) for IgG against each OspA serotype ST1 to ST6, determined by ELISA

    Time frame: Day 0, 28, 56, 84, 180, 236 and 365

  9. SCRs (Seroconversion Rate, defined based on fold increase of each OspA serotype specific IgG (ST1 to ST6) as compared to baseline)

    Time frame: Day 28, 56, 84, 180, 236 and 365

  10. GMFR (Geometric Mean of the fold rise as compared to baseline) for IgG against each OspA serotype ST1 to ST6, determined by ELISA

    Time frame: Day 28, 56, 84, 180, 236 and 365

07

Study locations

5 sites
  • eStudy Site
    La Mesa, California 91942, United States
  • eStudySite
    La Mesa, California 91942, United States
  • Celerion Inc.
    Lincoln, Nebraska 68502, United States
  • Celerion, Inc
    Lincoln, Nebraska 68502, United States
  • University Hospital Ghent
    Ghent, 9000, Belgium
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2017 to primary completion in Sep 2017, 7 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 21, 2016
First posted
Jan 4, 2017
StartActual
Jan 31, 2017
Primary completionActual
Sep 28, 2017
CompletionActual
Jan 16, 2019
Last update
Apr 5, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 5, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03010228
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Jan 4, 2017
Start date
Jan 31, 2017
Primary completion
Sep 28, 2017
Completion
Jan 16, 2019
Last update
Apr 5, 2023

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer
Pfizer CT.gov Call Center
principal investigator · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: VLA15 · Aluminum sulfate · Aluminium sulfate

Start the discussion